<DOC>
	<DOC>NCT00758862</DOC>
	<brief_summary>A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic Lesions (SITL). A total of 20 patients will be enrolled.</brief_summary>
	<brief_title>The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo</brief_title>
	<detailed_description />
	<mesh_term>Impetigo</mesh_term>
	<criteria>Ability and willingness to comply with all the study requirements/procedures Age ≥ 18 and ≤65 years Primary bullous/nonbullous impetigo or SITL Patients suffering from primary bullous/nonbullous impetigo must have: Not more than 10 discrete lesions, and A total lesional area ≥ 1 cm2 and ≤ 100 cm2, and Any surrounding erythema must not extend beyond 2 cm from the edge of the lesion, and Total SIRS score equal to or ≥ 8 Patients suffering from SITL must have: A total infected area of the traumatic lesion ≥ 1 cm2 and ≤ 100 cm2, and Any surrounding erythema must not extend beyond 2 cm from the edge of the lesion, and Total SIRS score ≥ 8, and SITL not caused by burns or animal/human bite Amenable for treatment with topical antibiotic alone Body Mass Index ≥18 and ≤ 35 kg/m2. Immunosuppressed state or other serious systemic disease Signs and/or symptoms of systemic infection, such as malaise and fever or local adenopathy and fever Unwillingness to abstain from use of any other topical products including emollients on the lesional area during the study Systemic treatment with antibacterials or immunosuppressive agents (e.g. corticosteroids) within 2 days before day 1 (inhaled/intranasal steroids may be used) Topical treatment with antibacterials, immunosuppressive agents (e.g. corticosteroids) or antiseptics (e.g. alcohol, chlorhexidine, hydrogen peroxide, iodine) on the lesional area within 2 days before day 1 Indication for surgical or systemic treatment of the SITL/impetigo Known or suspected hypersensitivity to any of the components of the study medication Participation in any other interventional clinical trial or use of an investigational drug within 30 days or 5 halflives (whichever is longer) prior to day 1 Previously enrolled in this study A blood alcohol content ≥ 0.08% as determined by a Breathalyzer test Known or suspected history of alcohol abuse/alcoholism or drug abuse Known or suspected impairment of liver function Heart rhythm disturbances or clinically significant quantitative or qualitative abnormality in the pretreatment ECG Blood donation in excess of 500mL within 56 days before day 1 or donation during the study or within 3 days of leaving the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>